Novartis rises to third place in the Access to Medicine Index

Novartis earns third place in the 2016 Access to Medicine Index ranking (in 2014 it was in 4th position) which measures every two years the performance achieved by the top 20 pharmaceutical companies in improving access to medicines and healthcare in countries where developing. The assessment takes into account seven metrics, including drug access management, resource capacity development, pricing, manufacturing and distribution.

«Novartis – ha dichiarato Joseph Jimenez, Ceo di Novartis. condivide l’obiettivo principale dell’Access to Medicine Index: colmare il divario che penalizza l’accesso ai farmaci da parte dei Paesi in via di sviluppo. Ci fa piacere che le nostre attività siano state riconosciute, ma occorre fare di più. Al fine di migliorare ulteriormente l’accesso, continueremo a lavorare alla creazione di approcci più scalabili e sostenibili, per migliorare l’accessibilità e la disponibilità di farmaci per i pazienti in condizioni più disagiate».

Novartis' efforts were recognized for two programs, in particular: Novartis Access, the portfolio of 15 covered and off-patent medicines to fight chronic diseases in low-income countries and ComHIP, a program supported by the Novartis Foundation and its partners to evaluate the impact of an innovative health care model for the control and self-management of hypertension in Ghana (Africa).

15 Novembre 2016 – HealthDesk

Related news: Access to Medicine Index 2016

Access to medicines, Johnson & Johnson second in the world

Gsk at the top of the Access to Medicine Index